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Background. Plasmodium knowlesi is increasingly reported in Southeast Asia, but prospective studies of its clinical spectrum in 
children and comparison with autochthonous human-only Plasmodium species are lacking.
Methods. Over 3.5 years, we prospectively assessed patients of any age with molecularly–confirmed Plasmodium monoinfection 
presenting to 3 district hospitals in Sabah, Malaysia.
Results. Of 481 knowlesi, 172 vivax, and 96 falciparum malaria cases enrolled, 44 (9%), 71 (41%), and 31 (32%) children aged 
≤12  years. Median parasitemia was lower in knowlesi malaria (2480/μL [interquartile range, 538–8481/μL]) than in falciparum 
(9600/μL; P < .001) and vivax malaria. In P. knowlesi, World Health Organization–defined anemia was present in 82% (95% confi-
dence interval [CI], 67%–92%) of children vs 36% (95% CI, 31%–41%) of adults. Severe knowlesi malaria occurred in 6.4% (95% 
CI, 3.9%–8.3%) of adults but not in children; the commenst severity criterion was acute kideny injury. No patient had coma. Age, 
parasitemia, schizont proportion, abdominal pain, and dyspnea were independently associated with severe knowlesi malaria, with 
parasitemia >15 000/μL the best predictor (adjusted odds ratio, 16.1; negative predictive value, 98.5%; P < .001). Two knowlesi-re-
lated adult deaths occurred (fatality rate: 4.2/1000 adults).
Conclusions. Age distribution and parasitemia differed markedly in knowlesi malaria compared to human-only species, with 
both uncomplicated and severe disease occurring at low parasitemia. Severe knowlesi malaria occurred only in adults; however, 
anemia was more common in children despite lower parasitemia. Parasitemia independently predicted knowlesi disease severity: 
Intravenous artesunate is warranted initially for those with parasitemia >15 000/μL.
Keywords. Plasmodium knowlesi; malaria; district; clinical epidemiology; children.
Since the initial description of a large focus of zoonotic 
Plasmodium knowlesi human cases in Sarawak, Malaysia, in 
2004 [1], knowlesi malaria has been reported from countries 
across Southeast Asia [2, 3]. In Malaysia, P.  knowlesi now 
accounts for >90% of all government-notified malaria cases 
[4–8], with >9500 reported cases from 2012 to 2016 [4, 5]. 
Plasmodium knowlesi is also increasingly reported in areas of 
western Indonesia [9, 10]. Difficulties with microscopic diag-
nosis [2, 11] have limited accurate reporting of the true inci-
dence of knowlesi malaria, with the disease burden likely 
underestimated [2, 5–7, 12]. Despite great progress in reducing 
human-only malaria species in many countries [4, 5], increasing 
numbers of P. knowlesi cases in Southeast Asia threaten regional 
malaria elimination. Conventional public health measures are 
unable to target zoonotic transmission to humans from the 
P. knowlesi reservoir in monkey hosts, particularly outdoors in 
agricultural or forest areas [13–16].
Prospective studies have described the clinical spectrum 
of naturally acquired adult knowlesi malaria [17, 18]. Severe 
knowlesi malaria has been reported in adults in Southeast 
Asia and in adult travelers returning from these regions [2, 12, 
18, 19], with the risk of severe disease at least as high as from 
Plasmodium falciparum [18]. Deaths from knowlesi malaria 
have been more common in older adults and have been associ-
ated primarily with respiratory distress, hypotension, and acute 
kidney injury (AKI) [6, 12, 19–21].
Malaria notification data in knowlesi-endemic areas show a 
median age of 31 years, much higher than that seen with P. fal-
ciparum and Plasmodium vivax [7], although 6% (79/1325) of 
all notified knowlesi malaria cases in Sabah in 2014 occurred in 
children aged <15 years [6]. With the marked reduction in cases 
of falciparum and vivax malaria, P. knowlesi now accounts for 
around 49% of all reported pediatric malaria cases in Sabah [6]. 
Despite this, there are limited descriptions of knowlesi malaria 
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in children [2, 22], or comparisons between zoonotic knowlesi 
malaria and locally acquired malaria from the human-only spe-
cies P. falciparum and P. vivax in district settings.
In this study, we compared the predefined clinical spectrum 
between children and adults with malaria due to P. knowlesi or 
other Plasmodium species infection, and evaluated predictors of 
disease severity in a coendemic primary care setting.
METHODS
Study Sites and Referral System
This study was conducted in Kudat Division, northwest Sabah, 
Malaysia, covering an area of 4623 km2 and with a total growth-
rate adjusted Malaysian census–estimated population in 2016 
of 199 600 people. Each of the 3 districts in this division has 
a central referral hospital and subdistrict health clinics, con-
sistent with other districts in Sabah. Malaysian Ministry of 
Health guidelines stipulate that all patients with fever receive 
microscopic blood slide screening for malaria parasites, with 
mandatory hospital admission, free treatment, and notification 
of positive cases [23].
Subjects
Patients of all ages presenting to study hospitals with 
microscopy-diagnosed malaria were enrolled following 
written informed consent. Children were predefined as age 
≤12  years, consistent with Malaysian Ministry of Health 
pediatric ward admission. Patients were not included in 
the final analysis if they were pregnant or had Plasmodium 
malariae infection on polymerase chain reaction (PCR), if 
Plasmodium species PCR was not confirmed, or if cross-
check research microscopy was negative. A subset of patients 
with uncomplicated P.  knowlesi and P.  vivax malaria was 
also enrolled in previously reported randomized controlled 
treatment trials [23–25].
Study Procedures
Baseline and longitudinal clinical, laboratory, and epidemio-
logical data were entered using standardized case record forms. 
Venous blood was taken for baseline investigations and then 
daily for microscopy and hematology during hospital admis-
sion and at the follow-up visit 28 days after treatment initiation. 
Severe malaria was defined using World Health Organization 
(WHO) 2014 research criteria [26], including for P.  know-
lesi: hyperparasitemia threshold of 100 000/μL, and jaundice 
defined as bilirubin >50  μmol/L with parasite count >20 000/
μL and/or creatinine >132  μmol/L [18]. Nonsevere anemia 
was defined using WHO age- and sex-based hemoglobin cri-
teria [27]. AKI was evaluated using Kidney Disease Outcomes 
Quality Working Group (KDIGO) criteria [28]. Chronic dis-
ease was defined as hypertension; diabetes mellitus; ischemic 
heart disease; hyperlipidemia; or chronic kidney, liver, or res-
piratory disease.
Laboratory Procedures
Microscopic asexual parasite and gametocyte counts were cal-
culated by research microscopists using thick blood smears 
and quantitated leukocyte count. Standard hospital automated 
hematology, biochemistry, and microbiology laboratory results 
were used. Final Plasmodium species confirmation was done 
using PCR [29, 30].
Statistical Analysis
We compared between-group differences with analysis of var-
iance or Kruskal-Wallis testing for continuous variables, and 
Student t test or the Wilcoxon–Mann-Whitney test for 2-group 
comparisons according to distribution. For categorical varia-
bles, χ2 or Fisher’s exact test was used. Logistic regression mod-
els were fitted to determine a priori predictors of severe malaria 
based on standard clinical and laboratory WHO 2014 research 
criteria [26] evaluable at time of acute patient presentation to 
district hospital settings, including testing for model interac-
tions and collinearity. Receiver operating characteristic (ROC) 
analysis was used to assess their sensitivity and specificity. 
Multivariate analysis controlled for age and loge parasitemia; 
patients with hyperparasitemia as a sole severity criterion were 
considered nonsevere.
Ethical Considerations
This study was approved by the medical research ethics com-
mittees of the Ministry of Health, Malaysia; London School of 
Hygiene and Tropical Medicine, United Kingdom; and Menzies 
School of Health Research, Australia.
RESULTS
Demographics
From October 2012 until April 2016, 811 malaria patients were 
enrolled (Figure  1). There were 481  P.  knowlesi, 172 P.  vivax, 
and 96 P.  falciparum malaria cases included in the final ana-
lysis. From 2014 to 2015, the estimated minimum yearly malaria 
incidence in Kudat Division (district hospital presentations with 
clinical disease) for P. knowlesi, P. vivax, and P. falciparum was 
0.79, 0.40, and 0.19 cases per 1000 people per year, respectively. 
Patients with knowlesi malaria had a median age of 33  years 
(interquartile range [IQR], 21–49 years), higher than those with 
vivax (15  years [IQR, 9–30  years]) and falciparum (16  years 
[IQR, 10–31 years]) malaria (P < .001; Figure 2). Patients aged 
>50 years comprised 107 (22%) of knowlesi malaria cases, com-
pared to 10 (6%) and 14 (15%) for falciparum and vivax malaria, 
respectively (P < .001). A bimodal age distribution was seen for 
females with both P.  knowlesi and P.  falciparum infection. Of 
P. knowlesi cases, 44 (9%) were children, compared to 71 (41%) 
of P. vivax cases and 31 (32%) of those with P. falciparum malaria 
(Table 1; P < .001). Only 6 (1.3%) knowlesi cases were <5 years 
of age, with only 1 infant (<1 year), a 6-week-old with no travel 
history or forest or plantation exposure. Compared to children 
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with P. knowlesi malaria, adults were more likely to be male (79% 
vs 57%; P = .001), with this relationship also evident for P. vivax 
cases (75% vs 48%; P < .001).
Baseline Features: Children
Abdominal pain was more common in children with know-
lesi compared to vivax malaria (43% vs 13%; odds ratio [OR], 
5.2 [95% confidence interval {CI}, 2.1–13.1]; P < .001), although 
vomiting occurred more often in those with P.  vivax (P =  .033) 
(Table  1). Children with knowlesi malaria had lower parasite 
counts than those with P. vivax (median, 1722 vs 5967 parasites/μL; 
P <  .001) and P.  falciparum (median, 1722 vs 7392 parasites/μL; 
P  <  .001). The highest parasite count recorded for a child with 
knowlesi malaria was 74 365/μL, in an 11-year-old boy with 
uncomplicated disease. There were 36 (84%) children with know-
lesi malaria with nonsevere anemia at presentation, comparable to 
children with other Plasmodium species infection, with no rela-
tionship to parasitemia demonstrated. The lowest hemoglobin 
level of 5.1  g/dL was seen in a 4-year-old child with knowlesi 
malaria 2 days after treatment, with 2 other children having min-
imum hemoglobin levels of 7.0 g/dL, all of whom had a parasite 
count <1000/μL at presentation. Children with knowlesi malaria 
had lower neutrophil and lymphocyte counts on presentation com-
pared to those with other Plasmodium species (P = .002). Thirty 
(68%) children with knowlesi malaria had thrombocytopenia 
(platelet count <150 ×  103/μL), including 4 (9%) with a platelet 
count <50 × 103 cells/μL. Frequency of thrombocytopenia in chil-
dren with knowlesi malaria was comparable to those with P. vivax 
but more common than with P. falciparum malaria (OR, 3.0 [95% 
CI, 1.1–7.7]; P = .026). Children with knowlesi malaria were more 
likely to develop mild to moderate AKI compared to those with 
P. vivax (26% vs 10%; OR, 3.1 [95% CI, 1.1–8.7]; P = .030).
Baseline Features: Adults
Duration of fever for P. knowlesi–infected adults was comparable 
to both children with P. knowlesi and adults with malaria due to 
Figure 1. Enrollment flowchart. Abbreviations: PCR, polymerase chain reaction; Pf, Plasmodium falciparum; Pk, Plasmodium knowlesi; Pv, Plasmodium vivax.
Figure 2. Proportion of cases and median parasite count by age-group and Plasmodium spp.
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Table 1. Baseline Demographic, Clinical, and Laboratory Features of Children
Patient Characteristic Plasmodium knowlesi Plasmodium vivax Plasmodium falciparum P Value
Children (age ≤12 y), No. (% total) 44 (9.1) 71 (41.3) 31 (32.3) <.001
Age, y
 Median (IQR) 8 (5–10) 9 (5–10) 7 (3–10) .095
 Range 0.1–12 0.67–12 1–12
Male sex, No. (%) 25 (56.8) 34 (47.9) 21 (67.7) .170
Previous malaria (self-reported), No. (%) 4 (9.1) 11 (15.5) 3 (9.7) .526
History of chronic disease, No. (%) 2 (4.5) 0 0 .095
Days of fever 5 (3–7) 5 (3–7) 4 (3–5) .751
Symptoms on enrollment, No. (%)
 Rigors 29 (65.9) 55 (77.5) 14 (45.2) .006
 Headache 34 (77.3) 55 (77.5) 21 (67.7) .542
 Vomiting 14 (31.8) 37 (52.1) 11 (35.5) .068
 Abdominal pain 19 (43.2) 9 (12.7) 9 (29.0) .001
 Diarrhea 4 (9.1) 2 (2.8) 4 (12.9) .140
 Cough 15 (34.1) 25 (35.2) 12 (38.7) .914
 Shortness of breath 3 (6.8) 4 (5.6) 4 (12.9) .431
 Myalgia 11 (25.0) 15 (21.1) 7 (22.6) .890
 Arthralgia 12 (27.3) 15 (21.1) 7 (22.6) .746
Examination findings on enrollment
 Temperature, °C 37.1 (36.8–37.9) 37.4 (36.8–37.8) 37.1 (36.8–38) .647
 Fever (≥37.5°C), No. (%) 17 (38.6) 33 (46.5) 12 (38.7) .634
 Systolic blood pressure, mm Hg 101 (94–109) 102 (96–110) 106 (98–112) .356
 Heart rate, beats/min 104 (93–119) 105 (94–118) 117 (96–134) .688
 Respiratory rate, breaths/min 24 (22–27) 24 (22–28) 26 (24–28) .081
 Oxygen saturation, % 99 (99–100) 99 (98–100) 100 (99–100) .504
 Palpable liver, No. (%) 14 (31.8) 20 (28.2) 8 (25.8) .842
 Palpable spleen, No. (%) 9 (20.5) 12 (16.9) 2 (6.5) .244
 Rash, No. (%) 1 (2.3) 0 (0) 1 (3.2) .360
Parasite count/μL 1722 (386–4830) 5967 (1829–13 901) 7392 (1462–36 546) <.001
Parasite count/μL, range 36–74 365 109–140 500 61–635 415
Schizont proportion, mean % (SD) 3 (7.5) 1 (4.0) 0 (0) .013
Schizont proportion >10%, No. (%) 3 (6.8) 1 (1.5) 0 (0) .138
Parasite count >20 000/μL, No. (%) 4 (9) 8 (11) 12 (39) .001
Gametocytes present, no./No. (%) 4/35 (11) 21/66 (32) 1/11 (9) .035
Hemoglobin, g/dL 10.6 (9.7–11.3) 10.1 (9.3–11.2) 10.3 (9.2–11.6) .726
Anemiaa (baseline), No. (%) 36 (82) 56 (79) 21 (68) .328
G6PD deficiency present, no./No. (%) 1/38 (2.6) 3/69 (4.3) 1/18 (5.6) .852
White blood cell count, × 103/μL 6.1 (5.1–7.5) 7.1 (5.1–8.6) 9.2 (6.4–12.7) .002
Neutrophil count, × 103/μL 2.7 (2.0–3.5) 3.3 (2.5–4.8) 3.8 (2.5–6.8) .015
Lymphocyte count, × 103/μL 2.0 (1.4–2.7) 2.2 (1.6–2.9) 2.8 (1.7–5.0) .025
Monocyte count, × 103/μL 1.1 (0.8–1.4) 0.9 (0.6–1.3) 1.2 (0.7–1.4) .241
Platelet count, × 103/μL 106 (80–163) 120 (93–179) 159 (83–282) .078
Platelet nadir, × 103/μL 78 (60–134) 104 (70–154) 129 (63–275) <.001
Platelet nadir, d 1 (0–1) 1 (0–1) 1 (0–1) 1.000
Thrombocytopenia (platelets <150 × 103/μL), No. (%) 30 (68) 46 (65) 13 (42) .047
Creatinine, μmol/L 48 (36–57) 48 (34–58) 40 (31–53) .267
Urea, mmol/L 3.8 (2.8–4.5) 3.5 (3.0–4.6) 3.2 (2.3–4.5) .167
Sodium, mmol/L 137 (135–139) 137 (136–139) 136 (133–139) .640
Bilirubin, μmol/L 11.5 (8.3–15.8) 9.8 (6.0–14.6) 11.0 (6.8–19.7) .474
Glucose, mmol/L 5.8 (5.1–6.8) 5.7 (5.0–6.4) 6.2 (5.6–6.6) .802
Albumin, g/dL 35 (31–37) 34 (28–36) 32 (29–37) .644
AST, IU/L 25 (23–34) 24 (15–28) 37 (24–42) .268
ALT, IU/L 16 (11–32) 17 (11–28) 24 (14–32) .270
Bicarbonate, mmol/L 23 (21–25) 22 (20–26) 25 (21–26) .418
Acute kidney injury, No. (%) 11 (26) 7 (10) 10 (32) .016
Blood culture positiveb, No. (%) 0/33 (0) 0/28 (0) 0/15 (0) 1.000
Data are presented as median (IQR) unless otherwise indicated. Results are from time of enrollment unless otherwise specified.
P values in bold font indicate a value <0.05.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; G6PD, glucose-6-phosphate dehydrogenase; IQR, interquartile range; SD, standard deviation.
aAnemia based on World Health Organization 2011 hemoglobin measurement criteria [27]: age 6–59 months (≤100 g/dL), 5–11 years (<115 g/dL), 12–14 years (<120 g/dL), nonpregnant women ≥15 years (<120 g/dL), pregnant 
women (<110 g/dL), men ≥15 years (<130 g/dL).
bExcluding results positive for skin contaminants.
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other Plasmodium species (Table 2). Adult P. knowlesi cases were 
less likely to report abdominal pain compared to children with 
knowlesi malaria (23% vs 43%; OR, 0.40 [95% CI, .2–.8]; P = .004; 
Supplementary Table  1). Adults with knowlesi malaria had 
lower parasite counts (median, 2541/μL) than those with vivax 
(median, 3765/μL; P =  .027) or falciparum (median, 9924/μL; 
P < .001) malaria (Table 2). Age was positively correlated with par-
asitemia in P. knowlesi (r2 = 0.15; P = .002), but not P. falciparum 
or P. vivax infection (Figure 2). Adult P. knowlesi cases had a 
lower risk of anemia at presentation compared to adults with 
vivax malaria (36% vs 50%, respectively; OR, 0.6 [95% CI, 
.4–.9]; P =  .013), and children with knowlesi malaria (36% vs 
82%; OR, 0.13 [95% CI, .06–.28]; P < .001). As with children, 
in adult knowlesi malaria parasitemia was not associated with 
anemia at enrollment after controlling for age. Adults with 
knowlesi malaria had lower platelet counts than those with 
other Plasmodium species (P <  .001), with thrombocytopenia 
more common in adults compared to children with knowlesi 
malaria (92% vs 68%, respectively; P < .001). The risk of AKI 
was higher in adult P.  knowlesi patients compared to P.  vivax 
(19% vs 10%, respectively; OR, 2.1 [95% CI, 1.1–4.3]; P = .033), 
although this did not remain statistically significant after con-
trolling for age; and was also comparable to that seen in both 
adults with P.  falciparum and children with knowlesi malaria. 
Liver aminotransferases were higher in adults with knowlesi 
malaria compared to those with P.  vivax including after con-
trolling for age (P  =  .001). Of the 322 adults with knowlesi 
malaria who had blood cultures, only 1 grew a noncontaminant 
isolate, a 14-year-old with Neisseria meningitidis.
Severe Malaria
Plasmodium knowlesi was the most common cause of severe 
malaria, with 28 of 481 (5.8%) knowlesi cases having severe dis-
ease (Table 3), all of whom were adults (28/437; 6.4% [95% CI, 
3.9%–8.3%]. Of the severe knowlesi cases, 19 (68%) had severe 
malaria on presentation and 9 (32%) developed severe compli-
cations following commencement of treatment. A single sever-
ity criterion defined severe malaria in 16 (57%), with 12 (43%) 
patients having ≥2 criteria (Table 4). The most common sever-
ity criterion was severe AKI (creatinine >265 μmol/L), occur-
ring in 10 (35.7%) severe knowlesi patients, including a single 
patient who progressed to severe AKI on day 1 of admission. 
Eight (29%) knowlesi patients had hyperparasitemia >100 000/
μL, including 5 (18%) as a sole severity criterion. Parasite counts 
were higher in severe knowlesi compared to nonsevere know-
lesi malaria (median, 42 224 vs 2044 parasites/μL, respectively; 
P < .001). The platelet count was lower in severe vs uncompli-
cated knowlesi malaria (median, 56 vs 75 × 103 cells/μL, respec-
tively; P =  .004), neutrophil count was higher (median, 4.9 vs 
3.7 ×  103 cells/μL, respectively; P  =  .004), and proportion of 
patients with hyponatremia was higher (48% vs 28%, respec-
tively; P = .028). Five (18%) knowlesi patients had documented 
hypotension, all of whom had other severity criteria including 2 
patients with respiratory distress. Empiric antibiotic treatment 
was given to 9 (32%) patients with severe knowlesi malaria. 
Of the 4 severe P. vivax cases, 2 were children with hyperbil-
irubinemia and a parasite count >20 000/μL, both with mod-
erate anemia (hemoglobin nadir of 6.8  g/dL and 9.1  g/dL, 
respectively). The other 2 patients with severe vivax malaria 
were adults, including a 17-year-old female with severe anemia, 
and a 53-year-old man with hypotension and respiratory dis-
tress. There were 5 patients with severe falciparum malaria 
(5.2%), including 2 children. No patient with malaria from any 
Plasmodium species had coma.
Predictors of Severe Malaria
On multivariate logistic regression controlling for age and par-
asitemia, independent clinical and parasitological predictors of 
severe disease in knowlesi malaria included schizont propor-
tion >10%, abdominal pain, and dyspnea (Table  5). Among 
WHO laboratory severity criteria, creatinine, hemoglobin, 
bicarbonate, and bilirubin remained independent predictors of 
severe disease when patients with only a single WHO severity 
criterion based on these measures were reclassified as nonse-
vere. A parasite threshold of 15 000/μL had the best-combined 
sensitivity (74%) and specificity (87%) for predicting severe 
knowlesi malaria, with an area under the curve of 0.80 (95% CI, 
.71–.90) and a negative predictive value of 98.5%. Age ≥45 years 
was the best predictor of hyperparasitemia when controlling for 
other variables (adjusted OR, 4.9 [95% CI, 1.0–23.9]; P = .048). 
Adults with knowlesi malaria had a higher risk of severe disease 
compared to adult patients with vivax malaria (OR, 3.4 [95% 
CI, .8–14.5]; P  =  .098), and a comparable risk to falciparum 
malaria.
Case Fatalities
There were 2 deaths attributed to malaria, both P.  knowlesi, 
giving an overall P. knowlesi case fatality risk of 2 of 481 (0.4% 
[95% CI, 0.1%–1.5%]), or 2 of 437 (0.5% [95% CI, 0.1%–1.6%]) 
in adults. The P.  knowlesi–related deaths were a 62-year-old 
woman with hyperparasitemia (263 772/μL) and moderate AKI 
(creatinine: 224 μmol/L), who developed hypotension and acute 
respiratory distress [6], and a 50-year-old man presenting with 
severe AKI (creatinine: 609 μmol/L), parasitemia of 71 939/μL, 
and moderate anemia (hemoglobin: 9.9 g/dL).
DISCUSSION
This study is the largest series of P. knowlesi malaria cases to 
date, and the first to prospectively compare the clinical spec-
trum of disease between adults and children. Although 91% of 
knowlesi malaria cases were adults, morbidity in children was 
also demonstrated, with an 11-fold higher risk of anemia at 
presentation and a similar risk of mild to moderate AKI com-
pared to adults [1, 7]. The majority of adults with knowlesi 
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Table 2. Baseline Demographic, Clinical, and Laboratory Features in Adults
Patient Characteristic Plasmodium knowlesi Plasmodium vivax Plasmodium falciparum P Value
Adults (age >12 y), No. (% total) 437 (90.9) 101 (58.7) 65 (67.7) <.001
Age, y
 Median (IQR) 35 (25–50) 27 (17–35) 24 (16–47) <.001
 Range 13–85 13–70 1–12
Male sex, No. (%) 345 (78.9) 76 (75.2) 48 (73.8) .522
Previous malaria (self-reported), No. (%) 93 (21.3) 26 (25.7) 8 (12.7) .137
History of chronic disease, No. (%) 35 (8.0) 2 (2.0) 3 (4.6) .066
Days of fever 4 (3–7) 5 (3–7) 4 (3–6) .089
Symptoms on enrollment, No. (%)
 Rigors 359 (82.3) 86 (85.1) 49 (76.6) .369
 Headache 389 (89.0) 93 (92.1) 56 (86.2) .469
 Vomiting 105 (24.0) 43 (42.6) 28 (43.1) <.001
 Abdominal pain 102 (23.3) 25 (24.8) 18 (27.7) .734
 Diarrhea 36 (8.2) 10 (9.9) 7 (10.8) .726
 Cough 153 (35.0) 32 (31.7) 22 (33.8) .814
 Shortness of breath 70 (16.0) 20 (19.8) 10 (15.4) .630
 Myalgia 269 (61.6) 58 (57.4) 35 (53.8) .418
 Arthralgia 289 (66.1) 59 (58.4) 34 (52.3) .052
Examination findings on enrollment
 Temperature, °C 37.4 (37.0–38.1) 37.4 (36.9–38.0) 37.0 (36.8–38) .001
 Fever (≥37.5°C), No. (%) 215 (49.3) 47 (46.5) 23 (35.4) .634
 Systolic blood pressure, mm Hg 120 (110–130) 115 (106–125) 112 (106–125) .004a
 Heart rate, beats/min 88 (77–100) 92 (78–102) 92 (81–100) .025a
 Respiratory rate, breaths/min 20 (20–24) 20 (20–22) 21 (20–22) .260
 Oxygen saturation, % 98 (97–99) 99 (98–100) 99 (98–100) <.001
 Palpable liver, No. (%) 105 (24.0) 21 (20.8) 11 (16.9) .390
 Palpable spleen, No. (%) 26 (5.9) 9 (8.9) 6 (9.2) .404
 Rash, No. (%) 19 (4.3) 3 (3.0) 1 (1.6) .492
Parasite count/μL 2541 (478–8585) 3765 (1755–8122) 9924 (2522–22 860) <.001
Parasite count/μL, range 20–263 772 53–184 353 33–693 922
Schizont proportion, mean % (SD) 2 (5.4) 1 (2.1) 0 (0.1) <.001
Schizont proportion >10%, No. (%) 32/432 (7.4) 2/99 (2.0) 0 (0) .014
Parasite count >20 000/μL, No. (%) 64 (15) 7 (7) 21 (32) <.001
Gametocytes present, no./No. (%) 54/379 (14) 48/92 (52) 7/31 (23) <.001
Hemoglobin, g/dL 13.2 (12.1–14.3) 12.8 (11.2–14.2) 13.1 (11.3–14.4) .058
Anemia* (baseline), No. (%) 156 (36) 50 (50) 26 (41) .041
G6PD deficiency present, no./No. (%) 4/364 (1.1) 4/94 (4.3) 1/48 (2.1) .117
White blood cell count, × 103/μL 6.1 (5.1–7.6) 6.5 (5.3–7.8) 6.5 (5.1–8.0) .013
Neutrophil count, × 103/μL 3.5 (2.6–4.5) 4.0 (3.0–5.1) 4.2 (3.1–5.4) <.001
Lymphocyte count, × 103/μL 1.4 (1.0–1.9) 1.4 (1.1–2.0) 1.4 (1.0–2.3) .675
Monocyte count, × 103/μL 1.0 (0.7–1.4) 0.7 (0.5–1.0) 0.7 (0.5–1.0) <.001
Platelet count, × 103/μL 70 (50–103) 95 (66–134) 91 (54–149) <.001
Platelet nadir, × 103/μL 60 (42–83) 85 (56–115) 81 (44–135) <.001
Platelet nadir, d 1 (1-1) 1 (1-1) 1 (1-1) 1.000
Thrombocytopenia (platelets <150 × 103/μL), No. (%) 401 (92) 82 (81) 49 (75) <.001
Creatinine, μmol/L 88 (75–103) 78 (61–93) 75 (58–91) <.001
Urea, mmol/L 5.2 (3.8–6.8) 4.7 (3.5–5.8) 5.0 (3.5–7.2) .032
Sodium, mmol/L 136 (134–139) 137 (135–139) 136 (134–139) .819
Bilirubin, μmol/L 17.1 (11.8–24.6) 14.0 (7.6–23.0) 18.3 (10.2–30.0) .032
Glucose, mmol/L 6.4 (5.6–7.4) 6.3 (5.7–6.7) 6.3 (5.3–7.5) .272
Albumin, g/dL 36 (30–40) 34 (30–38) 32 (29–37) .011
AST, IU/L 34 (23–47) 10 (6–15) 28 (16–37) <.001
ALT, IU/L 37 (24–56) 23 (14–36) 36 (22–48) <.001
Bicarbonate, mmol/L 24 (21–27) 23 (21–25) 22 (20–24) .921
Acute kidney injury, No. (%) 83 (19) 10 (10) 17 (27) .018
Blood culture positiveb, No. (%) 1/322 (<1) 0/64 (0) 0/31 (0) 1.000
Data are presented as median (IQR) unless otherwise indicated. Includes 2 P. knowlesi and 1 P. falciparum uncomplicated malaria adult patients given single-dose treatment by public health workers prior to enrollment.
P values in bold font indicate a value <0.05.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; G6PD, glucose-6-phosphate dehydrogenase; IQR, interquartile range; SD, standard deviation.
*Anemia based on World Health Organization 2011 hemoglobin measurement criteria [18]: age 6–59 months (≤100 g/dL), 5–11 years (<115 g/dL), 12–14 years (<120 g/dL), nonpregnant women ≥15 years (<120 g/dL), pregnant 
women (<110 g/dL), men ≥15 years (<130 g/dL).
aComparisons did not remain statistically significant after controlling for age.
bExcluding results positive for skin contaminants; 1 patient with knowlesi malaria was positive for Neisseria meningitidis.
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malaria had uncomplicated disease and, compared to those 
with vivax and falciparum malaria, were older, with a lower 
risk of nonsevere anemia and a higher risk of thrombocyto-
penia, consistent with previous reports [1, 17, 18]. The lower 
parasitemia in both children and adults with clinical illness 
from P.  knowlesi infection compared with the human-only 
Plasmodium species may indicate a lower pyrogenic thresh-
old and greater inflammatory response, consistent with 
poor adaptation of this zoonotic parasite to the human host. 
Although P.  knowlesi has a 24-hour blood-stage life cycle in 
humans, the low parasitemia in most infections may indicate 
variable efficiency in human red blood cell (RBC) invasion 
[31]. Only a minority had high parasitemia, with parasitemia 
an independent predictor of severe knowlesi malaria overall. 
Notably, there was no coma or convulsions seen in any patient 
with knowlesi malaria, consistent with previous studies 
Table 3. Severe Malaria
Characteristic
Plasmodium knowlesi  
(N = 481)
Plasmodium vivax
(N = 172)
Plasmodium falciparum
(N = 96) P Value
Severe cases
 No. 28 4 5
 % 5.8 2.3 5.2 .225
 95% CI 3.9–8.3 0.6–5.8 1.7–11.7
Age, y
 Median 53 11 14 <.001
 IQR 43–64 4–35 2–16
 Range 13–78 3–53 1–26
Child age ≤12 y
 No. 0 2 2 .001
 % 0 2.8 6.5
Male sex
 No. 19 2 4 .709
 % severe 68 50 80
Parasitemia/μL
 Median 42 225 19 333 297 000 .031
 IQR 17 221–103 577 6076–43 680 85 505–635 415
P values in bold font indicate a value <0.05.
Abbreviations: CI, confidence interval; IQR, interquartile range.
Table 4. Severe Plasmodium knowlesi Malaria Characteristics
WHO Severity Criteria Definition No.
% Severe
(n = 28)
% Total
(n = 481)
Hyperparasitemia Parasite count >100 000/μL 8 28.6 1.7
Hypotension Systolic blood pressure <70 mm Hg in children or <80 mm Hg in adults 5 17.9 1.0
Impaired consciousness Glasgow coma score <11 in adults or Blantyre coma score <3 in 
children
0 0 0
Metabolic acidosis Plasma bicarbonate <15 mmol/L 3 10.7 0.6
Respiratory distress Oxygen saturation <92% on room air with a respiratory rate >30/min 2 7.1 0.4
Jaundice Total bilirubin >50 μmol/L; with parasite count >20 000/μL and/or creati-
nine level >132 μmol/L
8 28.6 2.0
Severe acute kidney injury Plasma or serum creatinine >265 μmol/L 10 35.7 2.1
Severe malarial anemiaa Hemoglobin concentration <5 g/dL in children, and <7 g/dL in adults 8 28.6 1.7
Hypoglycemia Blood or plasma glucose <2.2 mmol/L 1 3.6 0.2
Significant bleeding Including recurrent or prolonged bleeding from nose, gums, or veni-
puncture sites; hematemesis or melena
1 3.6 0.2
≥2 criteria 12 42.9 2.5
Severe criteria developed after presentation 8 28.6 1.7
Transfer to tertiary hospital 15 53.6 3.1
Admitted to ICU 10 35.7 2.1
Death 2 7.1 0.4
P values in bold font indicate a value <0.05.
Abbreviations: ICU, intensive care unit; WHO, World Health Organization.
aIncludes 2 Plasmodium knowlesi patients with serious underlying medical illness: 1 with worsening of known chronic kidney disease (acute kidney injury) and another with endometrio-
sis-associated bleeding (anemia).
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[6, 17, 18, 32]. No child with knowlesi malaria had severe 
manifestations (although borderline severe anemia was pres-
ent in one), in contrast to the severe disease found in pediatric 
falciparum and vivax malaria in this series and elsewhere [26].
A lower proportion of P. knowlesi infections were in children 
compared to those with P. vivax or P. falciparum. The lower inci-
dence of clinical disease from P.  knowlesi infection in infants 
and also older children has been attributed to epidemiological 
factors such as lower forest exposure [1, 13, 18], although con-
tributing age-related innate protective mechanisms are plau-
sible [33], and asymptomatic infection has been reported in 
children [34]. Most children with knowlesi malaria had anemia 
at enrollment, consistent with a previous retrospective report 
[22]. Although adults with knowlesi malaria had higher parasite 
counts, nonsevere anemia was more common in children, sug-
gesting that children may have a higher rate of uninfected RBC 
destruction and/or greater dyserythropoiesis, although under-
lying mechanisms and baseline community anemia prevalence 
require further investigation [35]. Children with knowlesi 
malaria had lower parasitemia and platelet counts compared 
to children with either P.  vivax or P.  falciparum infection, in 
addition to a lower neutrophil count compared to P.  vivax. 
However, there was a comparable risk of nonsevere anemia 
and AKI seen in P. knowlesi–infected children as in those with 
P. vivax or P. falciparum.
The proportion of adults with severe disease from P. know-
lesi infection was comparable to that seen in P. falciparum. The 
risk of severe knowlesi malaria in this primary referral setting in 
Sabah, 6.2% in adults, was similar to district hospital presenta-
tions in Sarawak (9.3%) [17], and lower than that demonstrated 
in a tertiary hospital setting of 29% [18]. Severe AKI was the most 
frequent severity criterion, and has commonly been reported in 
other adult studies [17, 18, 32]. Severe anemia was present in a 
larger proportion of adults with severe knowlesi malaria than 
in a previous tertiary-referral study, which reported anemia as 
a severe criterion in only 5% of adults, 1 of whom was sple-
nectomized [18]. Plasmodium knowlesi parasitemia [18, 32] and 
age [33] independently predicted severe disease in this study, in 
addition to abdominal pain and dyspnea, which have not been 
previously demonstrated. Parasite counts were higher in severe 
knowlesi malaria than in uncomplicated disease despite no dif-
ference in the number of preceding days of fever, which suggests 
differences in efficacy and tropism of normocyte invasion and 
parasite multiplication [31]. With age an independent risk fac-
tor for both parasitemia and severity, the immunosenescence 
that occurs with aging [33, 36] may also result in impaired con-
trol of parasite multiplication.
The pathophysiological mechanisms in severe knowlesi 
malaria are not well understood but likely differ from P. falcip-
arum, with coma remaining unreported and a lack of the retinal 
microcirculatory changes found in severe falciparum malaria 
[37]. With endothelial activation and systemic inflammation at 
least as high in response to P. knowlesi as in P. falciparum infec-
tion [33, 36], these processes also likely contribute to pathogen-
esis, particularly with the comparatively low parasite biomass 
able to produce severe disease observed in this study. The 
nature and role of microvascular accumulation of parasitized 
RBCs, a key mechanism of severe knowlesi malaria in rhesus 
macaques and also observed in a single human autopsy report 
[21], requires investigation. RBC deformability is reduced in 
proportion to disease severity in knowlesi malaria [38], how-
ever the role of hemolysis and endothelial dysfunction, other 
key pathogenic mechanisms also present in severe falciparum 
malaria [39], require further investigation. Phenotypic glu-
cose-6-phosphate dehydrogenase deficiency has been shown to 
protect against knowlesi malaria [13]. Other host genetic fac-
tors related to selection pressure from historical human-only 
Plasmodium transmission may also modulate disease severity.
Current knowlesi malaria management guidelines in Sabah 
recommend referral for tertiary care and initial treatment with 
intravenous artesunate for any patients >50  years of age or 
with a parasitemia >20 000/μL [18, 40]. Along with appropriate 
intravenous artesunate administration for severe malaria due 
to any Plasmodium species, these management guidelines have 
contributed to a decline in reported malaria case-fatality rate [6, 
18, 20]. In the current study, predictors were limited to severe 
disease given the low case-fatality rate, with a parasite threshold 
of 15 000 parasites/μL giving a high negative predictive value 
of 98.5%. A  conservative approach would be to recommend 
early administration of intravenous artesunate initially for any 
knowlesi malaria case with a parasite count above this thresh-
old, given the potential delay or inability to evaluate other labo-
ratory markers of severe disease in most primary care settings.
In conclusion, although the majority of cases are uncompli-
cated, P. knowlesi infection causes morbidity at comparatively 
low parasitemia in both adults and children. Adults are at risk 
of severe and fatal disease, in contrast to children, among whom 
this was not demonstrated. A conservative treatment approach 
utilizing parasite counts to predict severe disease is warranted.
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